Over the past several decades, vision researchers have recognized that cerebral/cortical visual impairment (CVI) is a leading cause of pediatric visual impairment in the US and other industrialized ...

A look at the current state of AI in diabetic eye disease and where the future may take us. Artificial intelligence (AI) and deep learning tools are now a part of many people’s daily lives, whether ...

Aurion Biotech, Inc. has appointed Donald Munoz as chief financial officer (CFO). Greg Kunst, Aurion’s CEO, commented on this news in the company’s press release 1, saying, “We are delighted to ...

Video content above is prompted by the following: How strictly do you adhere to the loading dose recommendations for new therapies in treatment-naive patients with neovascular age-related macular ...

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining ...

As part of the Johns Hopkins Wilmer Eye Institute’s MACULA 2025 and the 5th Annual Retina Festival, Christina Y. Weng, MD, MBA, gave a presentation titled “Home Monitoring for Age-Related Macular ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

In his presentation, David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial which demonstrated that superior vision and anatomic outcomes were observed with sozinibercept 2 ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1). In December 2024, a ...